Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program

Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead candidate for the treatment of (TB), was the first approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.


Read more

Related posts

Leave a Reply